Sun Pharmaceutical Industries Ltd has commenced phase-II clinical trial of AQCH, a phytopharmaceutical or a plant derived drug, for the treatment of covid-19. AQCH is the first phytopharmaceutical drug approved for clinical trials by the Drugs Controller General of India (DCGI) as a potential treatment therapy for covid-19.

The clinical trial, Sun Pharma said, will be conducted across 12 centres in India in 210 patients. The treatment duration will be 10 days. The results of the clinical trial are expected by October. Human safety study of AQCH has already been completed and the drug has been found safe at the recommended dose for phase-II study, the pharma company said in a statement.

‘AQCH has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with International Centre for Genetic Engineering and Biotechnology (ICGEB), Italy,’ said Dilip Shanghvi, managing director, Sun Pharma. AQCH, being developed for dengue, has shown broad antiviral effect in in-vitro studies and hence is being tested as a potential treatment option for covid-19.

Since 2016, Sun Pharma has been working closely with the Department of Biotechnology (DBT)-ICGEB, under Dr. Navin Khanna and Council of Scientific & Industrial Research-Indian Institute of Integrative Medicine (CSIR- IIIM) under Dr Ram Vishwakarma, to develop a phytopharmaceutical drug for dengue.

Read EquityPandit’s Nifty Outlook for the Week